Lineage Cell Therapeutics (LCTX) Reports In-Line Q3 EPS

Lineage Cell Therapeutics (NYSE: LCTX) reported Q3 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $2.27 million versus the consensus estimate of $510 thousand.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• MP Materials seen largely insulated after China export-control move
• Stifel Starts Victrex Plc. (VCT:LN) (VTXPF) at Buy